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Major histocompatibility class II (MHCII) molecules are loaded with peptides derived
from foreign and self-proteins within the endosomes and lysosomes of antigen present-
ing cells (APCs). This process is mediated by interaction of MHCII with the conserved,
non-polymorphic MHCII like molecule HLA-DM (DM). DM activity is directly opposed by
HLA-DO (DO), another conserved, non-polymorphic MHCII like molecule. DO is an MHCII
substrate mimic. Binding of DO to DM prevents MHCII from binding to DM, thereby inhibit-
ing peptide loading. Inhibition of DM function enables low stability MHC complexes to
survive and populate the surface of APCs. As a consequence, DO promotes the display
of a broader pool of low abundance self-peptides. Broadening the peptide repertoire the-
oretically reduces the likelihood of inadvertently acquiring a density of self-ligands that is
sufficient to activate self-reactiveT cells. One function of DO, therefore, is to promoteT cell
tolerance by shaping the visible image of self. Recent data also shows that DO influences
the adaptive immune response by controlling B cell entry into the germinal center reaction.
This review explores the data supporting these concepts.
Keywords: antigen presentation, MHC class II, HLA-DM, HLA-DO, autoimmunity, germinal center reaction, non-
obese diabetic, diabetes
INTRODUCTION
The detection of major histocompatibility class II (MHCII) mole-
cules displaying pathogen-derived peptides on antigen presenting
cells (APCs) by CD4 T cells is an essential step in the initiation
of adaptive immune responses. Counterintuitively, the major-
ity of surface expressed MHCII peptide (pMHCII) complexes
do not display pathogen-derived peptides. Rather, they are filled
with self-peptides. CD4 T cells are immunologically tolerant of
self-pMHCII complexes since inappropriate T cell activation con-
tributes to the development of autoimmune disease (1). The pre-
sentation of self-pMHCII complexes at appropriate times plays an
important role in tolerance by inducing the death of self-reactive
thymocytes or by rendering mature CD4 T cells functionally
non-responsive. Thus, tight control of MHCII peptide loading is
important for not only CD4 T cell activation to foreign antigens,
but also for establishing and maintaining CD4 T cell tolerance.
The binding of specific peptides to MHC is largely controlled by
the structural constraints inherent to allelic variations in MHCII.
However, MHCII peptide loading is impacted by other mecha-
nisms including antigen delivery into endosomal compartments,
proteolysis and by direct modulation of MHCII peptide loading by
the accessory molecules HLA-DM (DM) and HLA-DO (DO) (2).
The basic biosynthetic and cellular pathways by which MHCII
molecules acquire their peptide cargo are reviewed elsewhere
(3, 4). Briefly, MHCII αβ heterodimers associate with the non-
polymorphic invariant chain (Ii) during assembly in the endo-
plasmic reticulum. Ii occupies the peptide binding groove of the
MHCII preventing unfolded proteins and peptides from prema-
turely binding to MHCII in the ER. Ii also targets MHCII-Ii
complexes to late endosomal and lysosomal compartments where
Ii is degraded by resident proteases. Ii is not degraded to com-
pletion, instead small fragments of Ii, termed class II-associated
Ii peptides or CLIP remain bound in the MHCII peptide groove
(5, 6). CLIP must be removed from the groove prior to binding
of peptides derived from self and foreign antigens. This process
is mediated by interaction of the non-classical MHCII like mole-
cule, DM (H2-M in mice) with MHCII-CLIP complexes (7). DM
also stabilizes an empty and peptide receptive form of MHCII
and edits the repertoire of MHCII-bound peptides ensuring that
exceptionally stable pMHCII complexes are presented at the cell
surface (7, 8). Although it is recognized that DM is essential for
MHCII antigen presentation, the molecular mechanisms by which
DM mediates MHCII peptide loading remain unclear. Previous
studies combined with recent biochemical and crystallographic
studies, however, have shown that DM forms stable complexes
with empty MHCII (i.e., a short-lived transition state) and that
this interaction is disrupted by high-affinity peptide binding to
MHCII. Thus, when mixtures of low and high-affinity peptides
are present, as would be the case in vivo in endosomal and lyso-
somal compartments, DM favors the loading and subsequent cell
surface presentation of high stability pMHCII complexes (8–10).
DM mediated peptide loading of MHCII molecules is con-
trolled in DCs, B cells, and medullary thymic epithelial cells by the
interaction of DM with another class II-like molecule, DO (H2-
O in mice) (11). Although DO and DM are both non-classical
MHCII proteins, DO is structurally more closely related to classi-
cal MHCII proteins suggesting that DO might interact with DM in
a similar manner to that of MHCII. DM and MHCII first interact
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in endosomal compartments. In contrast, DM-DO association is
initiated in the ER and the complex is maintained during and
after transport to endosomal compartments (12). Additionally,
DM-MHCII interactions are weak, whereas DM-DO complexes
are exceptionally stable. The tight association of DM with DO
suggested that DO might alter DM function. Initial biochemical
studies showed that DM-DO complexes were completely inac-
tive in terms of their ability to catalyze MHCII peptide loading
in vitro, supporting that DO was an inhibitor of DM function
(13, 14). Human cell line-based transfection studies supported
this idea and showed that cells expressing DO have high levels of
MHCII-CLIP where as DO-negative cells have comparably lower
levels (15). Additionally, DO/H2-O is down regulated upon DC
and B cell activation, freeing DM from DO inhibition, presum-
ably resulting in optimal MHCII peptide loading upon pathogen
encounter in vivo (16–21). Collectively, these studies supported
that DO inhibited DM.
The impact of DO on DM function became less clear, how-
ever, when the consequence of DO expression on the presentation
of individual antigenic peptides was measured. These studies,
using pMHCII specific Abs, TCR transgenic T cells, primary T
cell lines, or T cell hybridomas to measure presentation, showed
that DO/H2-O expression unpredictably affected the presentation
of individual antigenic peptides (15). DO expression inhibits or
enhances presentation of some peptides, while the presentation of
other peptides is not affected. These results lead to the idea that
DO was not simply an inhibitor of DM but instead somehow it
both positively and negatively attenuated DM function.
Recent crystallographic, biochemical and mutagenesis stud-
ies, however, demonstrated that DO is undeniably an irreversible
inhibitor of DM, in agreement with initial biochemical studies
(22, 23). These studies showed that DO interacts with DM in a
manner that is nearly identical to MHCII. Thus, DO inhibits DM
by acting as a MHCII substrate mimic. The effect that DO has
on the pMHC repertoire is due to DO sequestering DM and pre-
venting it from functionally acting on MHCII to promote and/or
edit peptide loading. These data support a model in which the net
result of DO expression is an overall changed peptide repertoire
with overall increased peptide diversity displayed at the cell sur-
face in the context of MHCII (Figure 1). In resting APCs, high
levels of DO inhibit DM, thereby promoting the presentation of
low stability peptides; self-derived peptides that normally would
be edited from MHCII by free DM (i.e., not associated with DO).
The likely consequence is that resting APCs present a more com-
plex/diverse peptide repertoire. In contrast, when DO expression is
low or absent, such as in activated APCs, MHCII-bound peptides
are enriched for those with higher stability, such as many immun-
odominant peptides. Importantly, DM activity is never completely
extinguished by DO. In primary resting APCs (high DO), DM is
always expressed in excess of DO with estimates indicating that
~30–50% of DM is free (16, 24). Thus, the final pMHCII repertoire
is controlled by the ratio of free, active DM relative to the pool of
inactive DM-DO. Although many studies show that DO expression
alters peptide loading of MHCII, direct evidence showing that DO
affects the overall kinetic stability of the cell surface MHCII-bound
peptide repertoire is lacking. Nevertheless, as discussed below, even
potentially small changes in pMHCII presentation induced by DO
can have a profound impact on immune responses and modulate
autoimmunity.
H2-O INHIBITS IN VIVO IMMUNE RESPONSES
Essential functions for DM in the MHCII antigen presenta-
tion pathway have been established, however a role for DO has
remained enigmatic (2). While it is apparent that DO is a MHCII
FIGURE 1 |The impact of DO inhibition of DM on the
MHCII-bound peptide repertoire. Immature DCs and resting B cells
(bottom) express high levels of DO and thus have pools of active
endosomal DM as well as inactive DM-DO complexes that shape the
overall peptide repertoire. The net result is a broad, diverse set of
lower stability peptides presented on MHCII. Self-peptides (red)
including CLIP (black peptide) are well represented. Activated DCs
and B cells and other DO-negative APC (top) are enriched for DM due
to DO downregulation and thus display a more focused and high
stability peptide repertoire. Self-peptide presentation including CLIP
is reduced at the expense of high stability peptide presentation
promoted by fully active DM editing.
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mimic that binds to and inhibits DM, the biological consequences
of DO inhibition of DM are less obvious. The generation and char-
acterization of H2-O deficient mice have, for the most part, been
disappointing in terms of providing decisive information about
H2-O function in vivo. Nevertheless, limited peptide sequencing
studies and antigen presentation assays show that H2-O expression
results in an altered peptide repertoire (2, 25, 26).
The effect of H2-O expression on the presentation of individ-
ual epitopes is typically quite small (<2-fold) and variable (15).
The small effect is likely due to the presence of both active H2-M
and inactive H2-M/H2-O complexes; H2-O does not completely
extinguish H2-M activity. Most proteins, especially large proteins,
have multiple epitopes that bind MHCII and are presented. The
impact of H2-O on the presentation of individual peptides might
be unimpressive, yet the sum of changes for multiple epitopes from
a single antigen might significantly impact the immune response.
To test this idea, we set up a sensitive in vivo system to measure
antigen presentation (27).
Entrance of B cells into the germinal center response is a com-
petitive process that is dependent upon help from CD4 T follicular
helper cells (28). B cells expressing higher densities of specific
pMHCII complexes more effectively receive T cell help and dif-
ferentiate into germinal center B cells. A competition between
antigen specific B cells from wild type and H2-O deficient mice was
established by simultaneous transfer into wild type recipient mice.
After immunization, the ability of the transferred B cells to present
pMHCII, interact with T follicular helper cells and become ger-
minal center B cells was measured. For both antigens tested in this
system, H2-O deficient antigen specific B cells won the competi-
tion (~2- to 5-fold) (27). When presentation by the antigen specific
B cells was directly measured ex vivo with primary, polyclonal CD4
T cells, H2-O deficient antigen specific B cells presented slightly
better (<2-fold). Nevertheless, the net effect of the small change in
pMHCII levels enabled the H2-O deficient B cells to preferentially
obtain T cell help and become germinal center B cells. Thus, H2-
O expression established a higher threshold of presentation for B
cells to join the germinal center reaction. Importantly, downregu-
lation of H2-O upon GC entry removes this barrier to presentation
(16, 17). Germinal center B cells undergo somatic hypermutation
combined with rapid cellular proliferation, which is inherently
dangerous. Thus, inhibition of antigen presentation by H2-O may
limit the ability of B cells to gain access to the germinal center in
the absence of a significant immunological challenge. In turn this
helps to prevent the negative consequences of the germinal center
reaction such as lymphoma and leukemia.
Recent studies also examined the impact of H2-O deficiency on
B cell immune responses (29). These studies showed that H2-O
deficient mice had slightly reduced IgG responses to two model
antigens early in the immune response (7 days) but not after. Ex
vivo antigen presentation assays showed that presentation of the
two antigens by wild type splenocytes was slightly better than by
H2-O deficient cells. As in our studies, the effect of H2-O on pre-
sentation was subtle (≤2-fold) and may explain the initial decrease
in humoral responses in H2-O deficient mice. It is not completely
clear why these experiments support a positive role for H2-O in
generating humoral responses whereas our own studies supported
an inhibitory role. Perhaps it was because the two experimental
systems assayed different aspects of B cell biology. In our transfer
system, antigen specific (i.e., transgenic) wild type and H2-O defi-
cient B cells were transferred together into a wild type recipient,
removing potential differences in CD4 T cell repertories or B cell
populations (27). In the other study, H2-O deficient and wild type
mice were immunized directly (29). The delayed humoral response
in the H2-O deficient mice in these experiments might actually be
due to reported changes in the CD4 T cell repertoire. The impact
of H2-O in vivo during immune responses is complex, thus, it will
be important to continue to use sensitive immunological systems
to completely understand the function of this molecule.
MOUSE MODELS TO STUDY DO/H2-O FUNCTION
Primary human DCs and B cells show a direct correlation between
MHCII-CLIP levels and DO expression (15). MHCII-CLIP and
DO levels are high in naïve B cells, whereas activated germinal
center B cells have low levels of MHC-CLIP and DO, despite main-
taining high levels of DM (16, 17). Similar results are observed for
resting and activated human DCs (19). Thus, MHCII-CLIP lev-
els are a good surrogate readout for DO levels in human APCs.
MHCII-CLIP levels, however, do not correlate with H2-O levels
in mouse APCs, despite similar downregulation of H2-O upon
APC activation (18, 20, 21, 30). Additionally, MHCII-CLIP levels
are only marginally increased on the surface of mouse APCs from
H2-O deficient mice (29). Why MHCII-CLIP levels correlate with
DO expression in human cells but not mouse cells is unknown.
One possibility is that mouse B cells have a pool of free H2-O
(20, 30) whereas in human cells, DO is always found in a complex
with DM. This implies that the H2-M/H2-O complexes may be
less stable than the DM/DO complexes. Alternatively, there might
be functional differences between the mouse and human proteins.
This possibility is supported by data from transgenic mice we gen-
erated that expressed human DO in mouse DCs using the CD11c
promoter (CD1c-DO).
In these mice, similar to wild type APC, ~70% of H2-M was
complexed with DO in CD11c-DO transgenic mice and DO levels
were downregulated upon DC activation, showing that DO func-
tionally interacted with H2-M (21, 31). CD11c-DO DCs displayed
an altered set of MHCII-bound peptides compared to DCs from
non-transgenic mice when analyzed with monoclonal antibodies
(31). As DO expression increased, MHCII-CLIP also increased
while pMHCII levels decreased. This was identical to what was
observed for human APC. The increased inhibitory activity of
DO compared to H2-O might be due to higher affinity bind-
ing of DO to H2-M. However the DO inhibitory activity was
removed by downregulation of DO in activated DCs, resulting
in normal humoral responses upon immunization with model
antigens (31, 32). Furthermore, measuring antigen presentation
by CD11c-DO DCs to model antigens showed minimal differ-
ences (31). Thus, DO expression had a profound impact on the
display of self-pMHCII at the cell surface but did not compromise
immunity.
DO/H2-O AND AUTOIMMUNITY
The biologically relevant question in terms of DO/H2-O function
is why is an inhibitor of DM mediated peptide loading necessary
for proper function of the immune system? As an inhibitor of
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DM, the net effect of DO is not only to dampen overall presenta-
tion, but also to broaden the peptide repertoire by allowing lower
stability peptides to remain bound to MHCII. This idea is impor-
tant when considering that the majority of peptides presented in
non-activated APC are self-peptides. Thus, DO expression ensures
that a broad, low-level representation of self is presented. Full
T cell activation requires the specific engagement of multiple
pMHC complexes. Therefore, increased peptide diversity leads
to a decreased likelihood of activating self-reactive CD4 T cells.
Thus, DO/H2-O may help mediate tolerance and prevent the
development of autoimmune disease.
The presentation of islet-derived self-peptides by MHCII mol-
ecules on DCs is essential for the initiation of the T cell mediated
autoimmune diseases, such as type 1 diabetes (T1D) (33). Our
studies showed that DO expression in mouse DCs resulted in
a profound decrease in self-pMHC at the cell surface (31, 32).
We considered the possibility that DO expression in mouse DCs
might sufficiently alter MHCII presentation of islet antigens to
protect mice from T1D. To test this, the CD11c-DO transgene was
introduced into a spontaneous mouse model for T1D, the Non-
Obese Diabetic (NOD) mouse. CD11c-DO transgenic NOD mice
(NOD.DO) displayed an altered set of self-pMHCII and were com-
pletely protected from T1D (32). Protection was not likely due to
a change in central tolerance as NOD.DO mice had pathogenic T
cells. Regulatory T cell function was unaltered and, therefore, not
involved in protection. Perhaps most remarkably, Rag-1 deficient
NOD.DO mice did not develop diabetes after receiving fully acti-
vated, pathogenic CD4 T cells from NOD mice. Thus, protection
from T1D was due to DO inhibition of H2-M,which resulted in the
inefficient presentation of islet-derived self-peptides by DCs. The
identification what islet peptides are modulated by DO expres-
sion remains to be determined. Overall, these studies show that
DO expression can shape the overall self-pMHCII repertoire in an
immunologically relevant manner that promotes T cell tolerance
and prevents autoimmunity.
If the physiological function of DO/H2-O in the immune sys-
tem is to ensure that a broad, low-level of self-pMHC complexes
are presented as a mechanism to promote self tolerance, then H2-
O deficient mice should develop autoimmune disease. Consistent
with this, a recent study showed that older H2-O deficient mice
developed high IgG2a titers specific for dsDNA, ssDNA, and his-
tones, autoantibodies specificities often found in lupus (29). H2-O
deficient mice did not develop to full blown autoimmune disease
though, and did not develop renal disease, which is often observed
in lupus. Importantly, transfer studies showed that autoantibody
development required H2-O deficient CD4 T cells. These data sup-
port that H2-O deficiency results in the selection of a self-reactive
CD4 T cell repertoire that provides B cell help. However, the direct
impact of DO/H2-O in modulating the self-pMHCII repertoire
presented by thymic epithelial cells in the thymus, the cells that
mediate T cell selection, has yet to be directly assessed by direct
sequencing of MHCII-bound peptides from wild type and H2-O
deficient mice. Collectively, the finding that loss of H2-O in mice
results in the development of antinuclear antibodies together with
our data showing that DO expression in mouse DCs prevents T1D
support that DO/H2-O inhibition of H2-M alters self-pMHCII
presentation to promote self tolerance and avoid autoimmunity.
CONCLUSION
The presentation of disease relevant self-pMHCII (MHCII) mol-
ecules by APC is essential for the initiation of many autoimmune
diseases. The repertoire of peptides bound to MHCII is regu-
lated positively by DM and negatively by DO. DO squelching DM
activity ensures that a diverse, low-level of self-pMHC are pre-
sented at the cell surface which promotes tolerance and protects
from autoimmune disease development. Further experimentation
is warranted to substantiate these ideas and to better understand
the immunological consequences of DO inhibition of DM activity.
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